Meta-Analysis of Antibody-Drug Conjugate Efficacy in Advanced Urothelial Carcinoma

A 2025 systematic review and network meta-analysis synthesizes evidence from 30 clinical studies involving 3,631 patients with locally advanced or metastatic urothelial carcinoma. The analysis compares outcomes like overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) for various antibody-drug conjugate therapies. It was authored by Youran Dai and published on figshare under a CC BY 4.0 license.

Use Cases

• Compare hazard ratios (HR) for overall survival (OS) and progression-free survival (PFS) across different antibody-drug conjugate regimens.
• Analyze objective response rate (ORR) and disease control rate (DCR) outcomes from 5 RCTs and 25 single-arm trials.
• Assess the incidence rates of grade 3 or higher adverse events (AEs) associated with specific ADC agents like enfortumab vedotin.
• Validate network meta-analysis findings against the GRADE framework quality assessments reported in the review.

Strengths

• Aggregates data from 30 clinical studies, providing a broad evidence base.
• Includes results for 3,631 patients, offering substantial clinical sample size.
• Reports specific statistical outcomes like hazard ratios and confidence intervals for key efficacy metrics.

Limitations

• The underlying data is a synthesis of published studies; raw patient-level data is not available.
• Analysis is based on a document (DOCX) format, requiring manual extraction for computational analysis.
• Includes 25 single-arm trials, which may limit the strength of comparative conclusions versus randomized controlled trials.

Provenance

Source

Systematic review of PubMed, Embase, Cochrane Library, and Web of Science.

Collection Method

Network meta-analysis of clinical trial data following PRISMA guidelines, using RoB 2.0 and ROBINS-I tools.

Time Range

Literature search from database inception to September 2025.

Freshness

Last updated March 2026, with literature search current through September 2025.